Enanta Pharmaceuticals Inc. (ENTA)
NASDAQ: ENTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ENTA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $222.19M
- EPS (TTM)
- -$2.35
- Dividend yield
- None
- 52-week range
- 7.56 – 17.15
- Day range
- 7.56 – 8.06
- Volume / Avg
- 457.63K / 287.81K
- Beta
- —
- Shares outstanding
- 29.16M
52-week range
ENTA stock today
Shares of Enanta Pharmaceuticals (ENTA) finished lower on Nov 20 at $7.62, a drop of 4.51% or $0.36 per share, versus the S&P 500's 3.70% decline. At this level, ENTA sits near the bottom of its 52-week range of $7.56 to $17.15: 55.6% below the high, set on Dec 29, 2025 and 0.8% above the low. ENTA is down 51.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 40.1%.
Enanta Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Enanta Pharmaceuticals
Company profileEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jay R. Luly Ph.D.
- Headquarters
- Watertown, MA
- Employees
- 120
- IPO year
- 2013
- Website
- enanta.com
Financial highlights
Full financialsIn fiscal 2026, Enanta Pharmaceuticals generated $63.0 million in revenue, down 3.6% from fiscal 2025, its first annual decline since 2025. Enanta Pharmaceuticals reported a net loss of $68.2 million, compared with a loss of $81.9 million a year earlier. Operating margin was -99.0%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $63.00M | $65.32M | $67.64M | $79.20M | $86.16M |
| Growth | -3.56% | -3.42% | -14.61% | -8.07% | -11.24% |
| Net income | $-68.25M | $-81.89M | $-116.05M | $-133.82M | $-121.75M |
| EPS (diluted) | $-2.35 | $-3.84 | $-5.48 | $-6.38 | $-5.91 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$21.83+186.48%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.87 vs $-0.83
- Surprise
- -4.82%
ENTA news
All ENTA news- Enanta Pharmaceuticals Becomes Oversold (ENTA)Nasdaq
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026Nasdaq
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026Business Wire
- Unified Patent Court Rules Enanta Pharmaceuticals, Inc. Patent EP 4 051 265 InvalidNasdaq
- Enanta Pharmaceuticals, Inc. Announces Planned Retirement of CEO Jay R. Luly, Ph.D. by February 1, 2027Nasdaq
Enanta Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMRXImmuneering Corporation Class A | 3.38 | -2.03% | $218.90M | vs ENTA |
| RCKTRocket Pharmaceuticals Inc. | 1.95 | -7.58% | $217.74M | vs ENTA |
| KROSKeros Therapeutics Inc. | 11.08 | -2.72% | $217.44M | vs ENTA |
| PYXSPyxis Oncology Inc. | 1.81 | +7.74% | $216.49M | vs ENTA |
| ARCTArcturus Therapeutics Holdings Inc. | 7.45 | -1.97% | $214.73M | vs ENTA |
| CYPHCypherpunk Technologies Inc. | 1.41 | -18.02% | $210.15M | vs ENTA |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs ENTA |
| CAMPCAMP4 Therapeutics Corporation | 3.79 | -5.25% | $237.84M | vs ENTA |
Indexes, lists and sector
Enanta Pharmaceuticals stock FAQ
What is Enanta Pharmaceuticals's stock price today?
ENTA last traded at $7.62 as of Nov 20, 4:00 PM EST, down 4.51% on the day. Prices are delayed at least 15 minutes.
Who is Enanta Pharmaceuticals's CEO?
Dr. Jay R. Luly Ph.D. is the chief executive officer of Enanta Pharmaceuticals Inc., which has about 120 employees.
What is the ENTA 52-week high?
The 52-week high for ENTA is $17.15 and the 52-week low is $7.56. The stock is currently 55.6% below its high.